TY - JOUR
T1 - Circadian Regulator CLOCK Drives Immunosuppression in Glioblastoma
AU - Xuan, Wenjing
AU - Hsu, Wen Hao
AU - Khan, Fatima
AU - Dunterman, Madeline
AU - Pang, Lizhi
AU - Wainwright, Derek A.
AU - Ahmed, Atique U.
AU - Heimberger, Amy B.
AU - Lesniak, Maciej S.
AU - Chen, Peiwen
N1 - Funding Information:
Anderson Cancer Center) for the help with gene clustering for microglia. This work was supported by NIH R00 CA240896, DoD Career Development Award W81XWH-21-1-0380, NIH P50CA221747, Cancer Research Foundation Young Investigator Award, Lynn Sage Scholar Award, American Cancer Society Institutional Research Grant IRG-21-144-27, philanthropic donation from Mindy Jacobson and the Bill Bass Foundation, Northwestern University start-up funds, and the Robert H. Lurie Comprehensive Cancer Center.
Funding Information:
M.S. Lesniak reports grants from NIH during the conduct of the study; other support from Calidi Pharmaceuticals outside the submitted work. No disclosures were reported by the other authors.
Publisher Copyright:
© 2022 American Association for Cancer Research
PY - 2022/6
Y1 - 2022/6
N2 - The symbiotic interactions between cancer stem cells and the tumor microenvironment (TME) are critical for tumor progression. However, the molecular mechanism underlying this symbiosis in glioblastoma (GBM) remains enigmatic. Here, we show that circadian locomotor output cycles kaput (CLOCK) and its heterodimeric partner brain and muscle ARNT-like 1 (BMAL1) in glioma stem cells (GSC) drive immunosuppression in GBM. Integrated analyses of the data from transcriptome profiling, single-cell RNA sequencing, and TCGA datasets, coupled with functional studies, identified legumain (LGMN) as a direct transcriptional target of the CLOCK–BMAL1 complex in GSCs. Moreover, CLOCK-directed olfactomedin-like 3 (OLFML3) upregulates LGMN in GSCs via hypoxia-inducible factor 1-alpha (HIF1a) signaling. Consequently, LGMN promotes microglial infiltration into the GBM TME via upregulating CD162 and polarizes infiltrating microglia toward an immune-suppressive phenotype. In GBM mouse models, inhibition of the CLOCK–OLFML3–HIF1a–LGMN–CD162 axis reduces intratumoral immune-suppressive microglia, increases CD8þ T-cell infiltration, activation, and cytotoxicity, and synergizes with anti–programmed cell death protein 1 (anti–PD-1 therapy). In human GBM, the CLOCK-regulated LGMN signaling correlates positively with microglial abundance and poor prognosis. Together, these findings uncover the CLOCK–OLFML3–HIF1a–LGMN axis as a molecular switch that controls microglial biology and immunosuppression, thus revealing potential new therapeutic targets for patients with GBM.
AB - The symbiotic interactions between cancer stem cells and the tumor microenvironment (TME) are critical for tumor progression. However, the molecular mechanism underlying this symbiosis in glioblastoma (GBM) remains enigmatic. Here, we show that circadian locomotor output cycles kaput (CLOCK) and its heterodimeric partner brain and muscle ARNT-like 1 (BMAL1) in glioma stem cells (GSC) drive immunosuppression in GBM. Integrated analyses of the data from transcriptome profiling, single-cell RNA sequencing, and TCGA datasets, coupled with functional studies, identified legumain (LGMN) as a direct transcriptional target of the CLOCK–BMAL1 complex in GSCs. Moreover, CLOCK-directed olfactomedin-like 3 (OLFML3) upregulates LGMN in GSCs via hypoxia-inducible factor 1-alpha (HIF1a) signaling. Consequently, LGMN promotes microglial infiltration into the GBM TME via upregulating CD162 and polarizes infiltrating microglia toward an immune-suppressive phenotype. In GBM mouse models, inhibition of the CLOCK–OLFML3–HIF1a–LGMN–CD162 axis reduces intratumoral immune-suppressive microglia, increases CD8þ T-cell infiltration, activation, and cytotoxicity, and synergizes with anti–programmed cell death protein 1 (anti–PD-1 therapy). In human GBM, the CLOCK-regulated LGMN signaling correlates positively with microglial abundance and poor prognosis. Together, these findings uncover the CLOCK–OLFML3–HIF1a–LGMN axis as a molecular switch that controls microglial biology and immunosuppression, thus revealing potential new therapeutic targets for patients with GBM.
UR - http://www.scopus.com/inward/record.url?scp=85130896258&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85130896258&partnerID=8YFLogxK
U2 - 10.1158/2326-6066.CIR-21-0559
DO - 10.1158/2326-6066.CIR-21-0559
M3 - Article
C2 - 35413115
AN - SCOPUS:85130896258
SN - 2326-6066
VL - 10
SP - 770
EP - 784
JO - Cancer Immunology Research
JF - Cancer Immunology Research
IS - 6
ER -